Royal Bank of Canada reaffirmed their buy rating on shares of Ra Pharmaceuticals (NASDAQ:RARX) in a research note published on Tuesday, December 5th. They currently have a $18.00 price target on the stock.
A number of other research analysts also recently weighed in on RARX. Zacks Investment Research downgraded Ra Pharmaceuticals from a hold rating to a sell rating in a report on Tuesday, August 22nd. Jefferies Group set a $25.00 target price on Ra Pharmaceuticals and gave the company a buy rating in a research note on Friday, August 25th. Credit Suisse Group boosted their target price on Ra Pharmaceuticals from $19.00 to $23.00 and gave the company an outperform rating in a research note on Friday, November 10th. Finally, BMO Capital Markets restated an outperform rating and issued a $34.00 target price (up previously from $31.00) on shares of Ra Pharmaceuticals in a research note on Monday, December 4th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus target price of $23.20.
Ra Pharmaceuticals (RARX) traded up $0.03 on Tuesday, hitting $8.50. The stock had a trading volume of 115,614 shares, compared to its average volume of 416,947. The company has a market cap of $191.65, a P/E ratio of -3.44 and a beta of 4.75. Ra Pharmaceuticals has a 12 month low of $7.15 and a 12 month high of $27.84.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its position in shares of Ra Pharmaceuticals by 28.3% during the 2nd quarter. Vanguard Group Inc. now owns 346,602 shares of the company’s stock worth $6,496,000 after purchasing an additional 76,349 shares during the last quarter. Candriam Luxembourg S.C.A. lifted its position in shares of Ra Pharmaceuticals by 43.2% during the 3rd quarter. Candriam Luxembourg S.C.A. now owns 116,000 shares of the company’s stock worth $1,694,000 after purchasing an additional 35,000 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its position in shares of Ra Pharmaceuticals by 70.3% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 21,800 shares of the company’s stock worth $409,000 after purchasing an additional 9,000 shares during the last quarter. Citadel Advisors LLC acquired a new position in shares of Ra Pharmaceuticals during the 3rd quarter worth about $4,664,000. Finally, Nationwide Fund Advisors raised its holdings in Ra Pharmaceuticals by 1,078.4% in the 2nd quarter. Nationwide Fund Advisors now owns 32,842 shares of the company’s stock valued at $615,000 after acquiring an additional 30,055 shares in the last quarter. 69.64% of the stock is owned by institutional investors and hedge funds.
WARNING: “Ra Pharmaceuticals’ (NASDAQ:RARX) “Buy” Rating Reiterated at Royal Bank of Canada” was posted by Week Herald and is the property of of Week Herald. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://weekherald.com/2017/12/30/royal-bank-of-canada-reiterates-buy-rating-for-ra-pharmaceuticals-rarx.html.
Ra Pharmaceuticals Company Profile
Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.
Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.